Dyson Paul J, Sava Gianni
Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.
Dalton Trans. 2006 Apr 28(16):1929-33. doi: 10.1039/b601840h. Epub 2006 Mar 28.
The discovery of new metal-based antitumour drugs, whether cisplatin derivatives or those based on other metals, has been largely based on cell viability assays (IC50 values) and compounds that bind to DNA. This approach has been applied for more than 30 years during which time very few new drugs have entered clinical use. In this article we discuss what the future holds for metal-based drugs, in particular anti-metastasis drugs, in these enlightened times of the post genomic era.
新型金属基抗肿瘤药物的发现，无论是顺铂衍生物还是基于其他金属的药物，在很大程度上都基于细胞活力测定（IC50值）以及与DNA结合的化合物。这种方法已经应用了30多年，但在此期间进入临床使用的新药却寥寥无几。在本文中，我们将探讨在这个后基因组时代的开明时期，金属基药物，特别是抗转移药物的未来发展方向。
